Yaël P. Mossé

This paper identifies cell state-dependent and -independent immunotherapeutic targets in neuroblastoma by analyzing subtype-specific gene expression and validating targets through experimental methods.

This study identifies DLK1 as a potential immunotherapeutic target in neuroblastoma through integrative proteomic, transcriptomic, and epigenomic analysis.

This paper genomically characterizes 261 pediatric cancer patient-derived xenograft models to guide rational clinical trial design and drug development.